Stromal Vascular Fraction for Osteoarthritis of the Knee Regenerative Engineering.
Chinedu C UdeShiv ShahKenneth S OgueriLakshmi S NairCato T LaurencinPublished in: Regenerative engineering and translational medicine (2021)
Reports have implicated the increased inflammatory proteins within the joints as the main cause of osteoarthritis (OA). This has attracted interest towards addressing these inflammatory proteins as a way of treatment for OA. The concentrated cell-packed portion of the adipose product stromal vascular fraction (SVF) from liposuction or other methods possesses anti-inflammatory effects and has been acclaimed to heal OA. Thus, we searched for clinical evidence supporting their use, for OA treatment through examining the literature. Data from various hospitals support that joints treated with SVF provided a better quality of life to patients. Currently, there is at least one version of these products that are obtained and given back to patients during a single clinic visit, approved by the FDA.
Keyphrases
- knee osteoarthritis
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- stem cells
- prognostic factors
- bone marrow
- emergency department
- peritoneal dialysis
- cell therapy
- patient reported outcomes
- mesenchymal stem cells
- total knee arthroplasty
- type diabetes
- skeletal muscle
- single cell
- metabolic syndrome
- combination therapy
- deep learning
- adverse drug
- smoking cessation
- data analysis
- drug induced